A therapeutic and side effects comparison between Reditux and brand type (MabThera) in Diffuse Large B Cell Lymphoma (DLBCL)

Trial Profile

A therapeutic and side effects comparison between Reditux and brand type (MabThera) in Diffuse Large B Cell Lymphoma (DLBCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors CinnaGen
  • Most Recent Events

    • 07 Aug 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
    • 30 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top